Literature DB >> 31583546

Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.

Tracy-Ann Moo1, Maxine S Jochelson2, Emily C Zabor3, Michelle Stempel4, Monica Raiss4, Anita Mamtani4, Audree B Tadros4, Mahmoud El-Tamer4, Monica Morrow4.   

Abstract

BACKGROUND: The National Comprehensive Cancer Network (NCCN) endorses sentinel lymph node biopsy (SLNB) in patients with clinically positive axillary nodes who downstage after neoadjuvant chemotherapy (NAC). In this study, we compared the accuracy of post-NAC MRI to clinical exam alone in predicting pathologic status of sentinel lymph nodes in cN1 patients.
METHODS: We identified patients with T0-3, N1 breast cancer who underwent NAC and subsequent SLNB from March 2014 to July 2017. Patients were grouped based on whether a post-NAC MRI was done. MRI accuracy in predicting SLN status was assessed versus clinical exam alone.
RESULTS: A total of 450 patients met initial study criteria; 269 were analyzed after excluding patients without biopsy-confirmed nodal disease, palpable disease after NAC, and failed SLN mapping. Median age was 49 years. Post-NAC MRI was done in 68% (182/269). Patients undergoing lumpectomy vs mastectomy more frequently received a post-NAC MRI (88 vs 54%, p < 0.001). All other clinicopathologic parameters were comparable between those who did and did not have a post-NAC MRI. Thirty percent (55/182) had abnormal lymph nodes on MRI. Among these, 58% (32/55) had a positive SLN on final pathology versus 42% (53/127) of patients with no abnormal lymph nodes on MRI and 52% (45/87) of patients who had clinical exam alone (p = 0.09). MRI sensitivity was 38%, specificity was 76%, and overall SLN status prediction accuracy was 58%.
CONCLUSIONS: Post-NAC MRI is no more accurate than clinical exam alone in predicting SLN pathology in patients presenting with cN1 disease. Abnormal lymph nodes on MRI should not preclude SLNB.

Entities:  

Mesh:

Year:  2019        PMID: 31583546      PMCID: PMC6868340          DOI: 10.1245/s10434-019-07867-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Kelly K Hunt; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Huong T Le-Petross
Journal:  J Clin Oncol       Date:  2015-02-02       Impact factor: 44.544

2.  How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.

Authors:  Anita Mamtani; Andrea V Barrio; Tari A King; Kimberly J Van Zee; George Plitas; Melissa Pilewskie; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Lisa M Sclafani; Virgilio Sacchini; Hiram S Cody; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2016-05-09       Impact factor: 5.344

3.  Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy.

Authors:  Jiyoon Park; Eun Young Chae; Joo Hee Cha; Hee Jung Shin; Woo Jung Choi; Young-Wook Choi; Hak Hee Kim
Journal:  Eur J Radiol       Date:  2018-10-02       Impact factor: 3.528

Review 4.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.

Authors:  Michael L Marinovich; Nehmat Houssami; Petra Macaskill; Francesco Sardanelli; Les Irwig; Eleftherios P Mamounas; Gunter von Minckwitz; Meagan E Brennan; Stefano Ciatto
Journal:  J Natl Cancer Inst       Date:  2013-01-07       Impact factor: 13.506

5.  Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.

Authors:  Sara Javid; Davendra Segara; Parisa Lotfi; Sughra Raza; Mehra Golshan
Journal:  Ann Surg Oncol       Date:  2010-02-09       Impact factor: 5.344

6.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Authors:  Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

7.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

8.  Magnetic Resonance Imaging for Axillary Breast Cancer Metastasis in the Neoadjuvant Setting: A Prospective Study.

Authors:  Anne E Mattingly; Blaise Mooney; Hui-Yi Lin; John V Kiluk; Nazanin Khakpour; Susan J Hoover; Christine Laronga; M Catherine Lee
Journal:  Clin Breast Cancer       Date:  2016-11-23       Impact factor: 3.225

9.  Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Tina J Hieken; Judy C Boughey; Katie N Jones; Sejal S Shah; Katrina N Glazebrook
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

10.  The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.

Authors:  M B I Lobbes; R Prevos; M Smidt; V C G Tjan-Heijnen; M van Goethem; R Schipper; R G Beets-Tan; J E Wildberger
Journal:  Insights Imaging       Date:  2013-01-29
View more
  3 in total

1.  Does the false-negative rate for 1 or 2 negative sentinel nodes after neo-adjuvant chemotherapy translate into a high local recurrence rate?

Authors:  Nicole E Sharp; Darren B Sachs; Nicole M Melchior; Philip Albaneze; Salvatore Nardello; Elin R Sigurdson; Mengying Deng; Allison A Aggon; John M Daly; Richard J Bleicher
Journal:  Breast J       Date:  2021-03-11       Impact factor: 2.431

2.  Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.

Authors:  Bernd Gerber; Andreas Schneeweiss; Volker Möbus; Michael Golatta; Hans Tesch; David Krug; Claus Hanusch; Carsten Denkert; Kristina Lübbe; Jörg Heil; Jens Huober; Beyhan Ataseven; Peter Klare; Markus Hahn; Michael Untch; Karin Kast; Christian Jackisch; Jörg Thomalla; Fenja Seither; Jens-Uwe Blohmer; Kerstin Rhiem; Peter A Fasching; Valentina Nekljudova; Sibylle Loibl; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

3.  AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022.

Authors:  Maggie Banys-Paluchowski; Marc Thill; Thorsten Kühn; Nina Ditsch; Jörg Heil; Achim Wöckel; Eva Fallenberg; Michael Friedrich; Sherko Kümmel; Volkmar Müller; Wolfgang Janni; Ute-Susann Albert; Ingo Bauerfeind; Jens-Uwe Blohmer; Wilfried Budach; Peter Dall; Peter Fasching; Tanja Fehm; Oleg Gluz; Nadia Harbeck; Jens Huober; Christian Jackisch; Cornelia Kolberg-Liedtke; Hans H Kreipe; David Krug; Sibylle Loibl; Diana Lüftner; Michael Patrick Lux; Nicolai Maass; Christoph Mundhenke; Ulrike Nitz; Tjoung Won Park-Simon; Toralf Reimer; Kerstin Rhiem; Achim Rody; Marcus Schmidt; Andreas Schneeweiss; Florian Schütz; H Peter Sinn; Christine Solbach; Erich-Franz Solomayer; Elmar Stickeler; Christoph Thomssen; Michael Untch; Isabell Witzel; Bernd Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-30       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.